Precigen (NASDAQ:PGEN) Stock Price Up 7.5% – Should You Buy?

Precigen, Inc. (NASDAQ:PGEN)’s stock price was up 7.5% on Friday . The company traded as high as $3.55 and last traded at $3.5250. Approximately 384,621 shares traded hands during trading, a decline of 91% from the average daily volume of 4,062,133 shares. The stock had previously closed at $3.28.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday. HC Wainwright increased their price target on Precigen from $8.50 to $9.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Thursday, January 22nd. Finally, Wall Street Zen cut Precigen from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.50.

Precigen Trading Up 6.1%

The firm has a fifty day simple moving average of $4.30 and a 200-day simple moving average of $4.06. The firm has a market cap of $1.23 billion, a P/E ratio of -2.50 and a beta of 1.10. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.04 and a quick ratio of 3.95.

Insider Buying and Selling at Precigen

In related news, Director Randal J. Kirk sold 1,900,036 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $4.18, for a total value of $7,942,150.48. Following the transaction, the director directly owned 341,189 shares in the company, valued at $1,426,170.02. This trade represents a 84.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 47.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Precigen

Hedge funds and other institutional investors have recently made changes to their positions in the business. Patient Capital Management LLC lifted its position in Precigen by 62.6% in the 3rd quarter. Patient Capital Management LLC now owns 26,460,848 shares of the biotechnology company’s stock valued at $87,056,000 after acquiring an additional 10,192,107 shares in the last quarter. Lansing Street Advisors bought a new stake in Precigen during the 3rd quarter worth approximately $1,800,000. Diametric Capital LP purchased a new stake in shares of Precigen in the second quarter worth approximately $476,000. Profund Advisors LLC purchased a new stake in shares of Precigen in the third quarter worth approximately $79,000. Finally, Vontobel Holding Ltd. bought a new position in shares of Precigen in the third quarter valued at approximately $48,000. 33.51% of the stock is owned by institutional investors.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.